Fig. 3.
Treatment schema and target antigen expression of excised tumors. (A) Intratumoral treatment overview for the 4 cycles of 108 GRm13Z40-2 cells administered twice a week, with IL-2 administered by convection-enhanced delivery (CED) on days 2-5 of week one, and days 1-5 of week 2. (B) Recurrent tumors of each UPN resected at time of Rickham placement underwent immunohistochemical (IHC) staining using IL13Rα2-specific DAB with hematoxylin counterstain. Scale bars indicate 100 µm. H scores are indicated in parenthases, and were obtained by the formula: (3 x percentage of strongly staining cells) + (2 x percentage of moderately staining cells) + percentage of weakly staining cells, giving a range of 0 to 300 (Modified from11); plus signs indicate that membranous staining was observed.